European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

Author:

Ludwig Heinz1,Avet-Loiseau Hervé2,Bladé Joan3,Boccadoro Mario4,Cavenagh Jamie5,Cavo Michele6,Davies Faith7,Rubia Javier8,Delimpasi Sosana9,Dimopoulos Meletios10,Drach Johannes11,Einsele Hermann12,Facon Thierry13,Goldschmidt Hartmut14,Hess Urs15,Mellqvist Ulf-Henrik16,Moreau Philippe17,San-Miguel Jesús18,Sondergeld Pia19,Sonneveld Pieter20,Udvardy Miklos21,Palumbo Antonio4

Affiliation:

1. a Wilhelminenspital, Vienna, Austria;

2. b Laboratoire d'Hématologie, Institut de Biologie, Nantes, France;

3. c Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain;

4. d Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy;

5. e Department of Haematology, St Bartholomew's Hospital, London, United Kingdom;

6. f Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy;

7. g Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom;

8. h Hematology Service, University Hospital La Fe, Valencia, Spain;

9. i Evangelismos Hospital Hematology and Bone Marrow Transplantation, Athens, Greece;

10. j Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece;

11. k Department of Oncology, University Clinic, Vienna, Austria;

12. l Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany;

13. m Service d'Hématologie, Centre Hospitalier Universitaire (CHU), Lille, France;

14. n Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;

15. o Division of Oncology/Hematology, Kantonsspital, St. Gallen, Switzerland;

16. p Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden;

17. q University Hospital, Nantes, France;

18. r Servicio de Hematología, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain;

19. s Ammonite Systems Ltd., Faringdon, United Kingdom;

20. t Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands;

21. u Institute of Medicine, Medical and Health Science Centre, Debrecen, Hungary

Abstract

Abstract The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3